This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Beraprost 314d

United Therapeutics Corporation

Drug Names(s): Careload LA, YM533, Beraprost SR, Beraprost MR, TRK-100STP, Berasus LA, BPS-314d-MR, L-314d

Description: Beraprost sodium is an orally administered prostacyclin analog. Prostacyclin, although mainly involved in the prevention of platelet formation, is also an effective vasodilator.

Beraprost 214d is the isolated 314d isomer of beraprost. It is being dosed QID, versus BID for older beraprost studies. The QID dosing is being used both in order to reduce trough time, but also because the drug is anticipated to be used with inhaled Tyvaso, given QID.

Deal Structure: In March 2007, Lung Rx, a wholly-owned subsidiary of United Therapeutics Corporation, announced that it has entered into an agreement with Toray Industries to assume and restate the rights and obligations of the agreement entered into between United Therapeutics and Toray in June 2000 concerning the commercialization of modified release formulations of beraprost.

Partners: Toray Industries, Inc. Astellas Pharma, Inc.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug